Nicholas Coleman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4969045/publications.pdf

Version: 2024-02-01

46	2,245	236925	233421
papers	citations	25 h-index	45 g-index

50	50	50	3017
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment. Journal of Clinical Investigation, 2022, 132, .	8.2	21
2	Circulating microRNAs as biomarkers to assist the management of the malignant germ-cell-tumour subtype choriocarcinoma. Translational Oncology, 2021, 14, 100904.	3.7	12
3	Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. Journal of Urology, 2021, 205, 137-144.	0.4	28
4	The Road Ahead for Circulating microRNAs in Diagnosis and Management of Testicular Germ Cell Tumors. Molecular Diagnosis and Therapy, 2021, 25, 269-271.	3.8	6
5	Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection. European Urology Open Science, 2021, 26, 83-87.	0.4	26
6	Short- and long-range cis interactions between integrated HPV genomes and cellular chromatin dysregulate host gene expression in early cervical carcinogenesis. PLoS Pathogens, 2021, 17, e1009875.	4.7	18
7	A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor Diagnosis. Clinical Genitourinary Cancer, 2021, 19, 469-479.	1.9	19
8	The developmental origin of cancers defines basic principles of cisplatin resistance. Cancer Letters, 2021, 519, 199-210.	7.2	17
9	Pre-Implementation Assessment of the Acceptability of Using Circulating microRNAs for Follow-Up of Malignant Germ-Cell Tumors. Clinical Genitourinary Cancer, 2021, 19, 381-387.	1.9	4
10	Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review. European Urology, 2021, 80, 456-466.	1.9	60
11	A Circulating MicroRNA Panel for Malignant Germ Cell Tumor Diagnosis and Monitoring. Methods in Molecular Biology, 2021, 2195, 225-243.	0.9	4
12	Clinical utility of circulating miR-371a-3p for the management of patients with intracranial malignant germ cell tumors. Neuro-Oncology Advances, 2020, 2, vdaa048.	0.7	17
13	Can circulating microRNAs solve clinical dilemmas in testicular germ cell malignancy?. Nature Reviews Urology, 2019, 16, 505-506.	3.8	8
14	Cost Analysis of Noninvasive Blood-Based MicroRNA Testing Versus CT Scans for Follow-up in Patients With Testicular Germ-Cell Tumors. Clinical Genitourinary Cancer, 2019, 17, e733-e744.	1.9	25
15	Human papillomavirus genome integration in squamous carcinogenesis: what have nextâ€generation sequencing studies taught us?. Journal of Pathology, 2018, 245, 9-18.	4.5	46
16	Antiâ€oncostatin M antibody inhibits the proâ€malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma. Journal of Pathology, 2018, 244, 283-295.	4.5	22
17	â€œFuture-Proofingâ€•Blood Processing for Measurement of Circulating miRNAs in Samples from Biobanks and Prospective Clinical Trials. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 208-218.	2.5	28
18	Disruption of CTCF-YY1â€“dependent looping of the human papillomavirus genome activates differentiation-induced viral oncogene transcription. PLoS Biology, 2018, 16, e2005752.	5.6	60

#	Article	IF	Citations
19	STAT3 activation by E6 is essential for the differentiation-dependent HPV18 life cycle. PLoS Pathogens, 2018, 14, e1006975.	4.7	62
20	A Robust Protocol to Quantify Circulating Cancer Biomarker MicroRNAs. Methods in Molecular Biology, 2017, 1580, 265-279.	0.9	14
21	Identification of host transcriptional networks showing concentration-dependent regulation by HPV16 E6 and E7 proteins in basal cervical squamous epithelial cells. Scientific Reports, 2016, 6, 29832.	3.3	7
22	Paediatric extracranial germ-cell tumours. Lancet Oncology, The, 2016, 17, e149-e162.	10.7	60
23	The present and future of serum diagnostic tests for testicular germ cell tumours. Nature Reviews Urology, 2016, 13, 715-725.	3.8	148
24	Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelialâ€“mesenchymal transition and poor overall survival. British Journal of Cancer, 2016, 115, 212-222.	6.4	35
25	What Is Trophoblast? A Combination of Criteria Define Human First-Trimester Trophoblast. Stem Cell Reports, 2016, 6, 257-272.	4.8	213
26	A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours. British Journal of Cancer, 2016, 114, 151-162.	6.4	122
27	Chronic Hepatitis B Virus Infection: The Relation between Hepatitis B Antigen Expression, Telomere Length, Senescence, Inflammation and Fibrosis. PLoS ONE, 2015, 10, e0127511.	2.5	31
28	Pathogenesis of human papillomavirus-associated mucosal disease. Journal of Pathology, 2015, 235, 527-538.	4.5	119
29	CCCTC-Binding Factor Recruitment to the Early Region of the Human Papillomavirus 18 Genome Regulates Viral Oncogene Expression. Journal of Virology, 2015, 89, 4770-4785.	3.4	58
30	Solid Tumors of Childhood Display Specific Serum microRNA Profiles. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 350-360.	2.5	74
31	Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. Journal of Pathology, 2014, 232, 386-390.	4.5	68
32	Virus transcript levels and cell growth rates after naturally occurring HPV16 integration events in basal cervical keratinocytes. Journal of Pathology, 2014, 233, 281-293.	4.5	20
33	Regulation of human genome expression and RNA splicing by human papillomavirus 16 E2 protein. Virology, 2014, 468-470, 10-18.	2.4	30
34	Tissue transglutaminase mediates the proâ€malignant effects of oncostatin M receptor overâ€expression in cervical squamous cell carcinoma. Journal of Pathology, 2013, 231, 168-179.	4.5	31
35	Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a proâ€angiogenic phenotype and increased cell motility and invasiveness. Journal of Pathology, 2011, 225, 448-462.	4.5	34
36	In vitro Progression of Human Papillomavirus 16 Episome-Associated Cervical Neoplasia Displays Fundamental Similarities to Integrant-Associated Carcinogenesis. Cancer Research, 2010, 70, 4081-4091.	0.9	74

#	Article	IF	Citations
37	Characterization of Naturally Occurring HPV16 Integration Sites Isolated from Cervical Keratinocytes under Noncompetitive Conditions. Cancer Research, 2008, 68, 8249-8259.	0.9	83
38	Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3822-3827.	7.1	134
39	Langerhans cells and the cells of Langerhans cell histiocytosis do not express DC-SIGN. Blood, 2001, 98, 1987-1988.	1.4	40
40	Early genetic events in HPV immortalised keratinocytes. Genes Chromosomes and Cancer, 2001, 30, 72-79.	2.8	36
41	Detection of S-phase cells in tissue sections by in situ DNA replication. Nature Cell Biology, 2000, 2, 244-245.	10.3	21
42	Cellular and Subcellular Distribution of Polycystin-2, the Protein Product of the PKD2 Gene. Journal of the American Society of Nephrology: JASN, 2000, 11, 814-827.	6.1	145
43	Novel method for the production of multiple colour chromosome paints for use in karyotyping by fluorescence in situ hybridisation. , 1999, 25, 241-250.		36
44	Characterization and functional analysis of the expression of vascular adhesion molecules in human papillomavirus-related disease of the cervix. Cancer, 1994, 74, 884-892.	4.1	37
45	Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. International Journal of Cancer, 1994, 56, 314-319.	5.1	61
46	â€œNaturalâ€•presentation of human papillomavirus type-16 E7 protein to immunocompetent mice results in antigen-specific sensitization or sustained unresponsiveness. European Journal of Immunology, 1994, 24, 738-745.	2.9	22